Home/Sudo Biosciences/Scott Byrd

SB

Scott Byrd

Chief Executive Officer

Sudo Biosciences

Therapeutic Areas

Neurological Immunological

Sudo Biosciences Pipeline

Drug	Indication	Phase
SUDO-550	Neurological & Immunological Conditions (e.g., Multiple Sclerosis)	Phase 1

Leadership Team at Sudo Biosciences

Ian Mills, BM, BCh, DM

Chief Medical Officer

Gordon McMurray, PhD

Chief Development Officer

Imran Babar, PhD

Chief Business & Financial Officer

View full Sudo Biosciences profile